<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580707</url>
  </required_header>
  <id_info>
    <org_study_id>SAIRB-18-0016</org_study_id>
    <nct_id>NCT03580707</nct_id>
  </id_info>
  <brief_title>Does BRV Have Faster Onset Time &amp; Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint</brief_title>
  <official_title>Does BRV Have a Faster Onset Time and Greater Effect Than LEV in Epilepsy Patients?: A Prospective, Randomized, Crossover, Double-blind, Controlled Intravenous Study Using the PPR as a Pharmacodynamic Efficacy Endpoint</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rosenfeld, William E., M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Comprehensive Epilepsy Care Center for Children &amp; Adults</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Utrecht University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rosenfeld, William E., M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to see whether brivaracetam has a faster onset time and
      greater effect than levetiracetam in subjects with photosensitive seizures. Part 1 of the
      study will compare the effects of levetiracetam 1500 mg with the effects of brivaracetam 100
      mg. Part 2, will compare the effects of levetiracetam 1500 mg with the effects of
      brivaracetam 100 mg or will compare the effects of levetiracetam 500mg with the effects of
      brivaracetam 25 mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study in epilepsy patients with photosensitivity intends to extend the animal
      findings for the faster (and perhaps greater) pharmacodynamic effect of intravenous BRV
      versus LEV at equipotent doses. Doses and infusion times were chosen based on proven safety
      profiles of both drugs (UCB, data on file): maximal dose of 1500 mg LEV in 15 minutes (or in
      5 minutes) and 100 mg for BRV (15 times more potency of BRV compared to LEV). The study
      proposes a comparison of the rapidity of the CNS effects of both LEV and BRV within the same
      patient (randomized, two-way crossover, double-blind in a total 16 patients with epilepsy 8
      patients in Part 1 and 8 patients in Part 2) Study Part 1: an IV infusion over 15 minutes,
      appropriately diluted (per package insert for LEV); BRV will also be administered as a
      15-minute infusion (anticipating similar language in the package insert for BRV);Study Part
      2, Option I: Assuming a statistically significant difference in the rapidity of CNS action
      has been observed from an analysis of the data set in Study Part 1, will proceed with Study
      Part 2 Option I. LEV or BRV will be administered, in a randomized, two-way crossover,
      double-blind design as an IV infusion over 5 minutes, appropriately diluted, to another
      cohort of 8 patients with photosensitive epilepsy. (Potentially, a few of the same patients
      as under 'a' above could participate herein, if they are willing to repeat the study). OR
      Study Part 2, Option II: Assuming no statistically significant difference in the rapidity of
      CNS action has been observed from an analysis of the data set in Study Part 1, will proceed
      with Study Part 2, Option II. LEV or BRV will be administered, in a randomized, two-way
      crossover, double-blind design as an IV infusion over again 15 minutes, appropriately
      diluted, to another cohort of 8 patients with photosensitive epilepsy. (Potentially, a few of
      the same patients as under 'a' above could participate herein, if they are willing to repeat
      the study). However, LEV will be given as a 500 mg dose, and BRV as a 25 mg dose. Use of
      lower, nearly equipotent minimally effective doses of LEV and BRV will maximize ability to
      readily differentiate the electroencephalographic PPR effect between the two AEDs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>&quot;Comparison between Brivaracetam and Levetiracetam of the Time to Peak Effect (Abolition) and Time to &gt;50% Diminution in Photo-Paroxysmal Response in Patients with Photosensitive Epilepsy&quot; (1)</measure>
    <time_frame>Six weeks</time_frame>
    <description>Difference in time (minutes) required between drugs, BRV&amp; LEV to abolish a PPR (photo-paroxysmal response on the pts encephalogram, EEG) after intermittent photic stimulation (IPS) tested in the same pt of 2 separate occasions. In Pt 1, 8 pts w/photosensitive epilepsy will be studied in double-blind, crossover fashion with 15-minute linear intravenous (i.v.) infusion of either 1500 mg LEV or BRV 100 mg as single dose. After 2 weeks, each pt will be tested in identical fashion w/opposite drug (crossover). Pt 2, Option 1, 8 pts w/photosensitive epilepsy will be studied in double-blind, crossover fashion. Same single mg doses of LEV and BRV will be used, but i.v. infusion time will be 5 minutes;primary outcome measure will be same.Part 2, Option 2, 8 pts w/photosensitive epilepsy will be studied in double-blind, crossover fashion. Single mg i.v. dose of 500 mg LEV or 25 mg BRV will be used, w/infusion time over 15 minutes;primary outcome measure will be the same.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>&quot;Comparison between Brivaracetam and Levetiracetam of the Time to Peak Effect (Abolition) and Time to &gt;50% Diminution in Photo-Paroxysmal Response in Patients with Photosensitive Epilepsy&quot; (2)</measure>
    <time_frame>Six weeks</time_frame>
    <description>Difference in time (minutes) required between drugs,BRV &amp; LEV to produce a &gt;50% decrease in PPR (photo-paroxysmal response on pts encephalogram, EEG) after intermittent photic stimulation (IPS) tested in same pt of 2 separate occasions. Pt 1, 8 patients w/photosensitive epilepsy will be studied in double-blind, crossover fashion w/15-minute linear intravenous (i.v.) infusion of either 1500 mg LEV or BRV 100 mg as single dose. After 2 weeks, each pt will be tested in identical fashion w/opposite drug (crossover). In Pt 2, Option 1, 8 pts w/photosensitive epilepsy will be studied in double-blind, crossover fashion. Same single mg doses of LEV and BRV will be used, but i.v. infusion time will be 5 minutes; primary outcome measure will be the same. Pt 2, Option 2, 8 pts w/photosensitive epilepsy will be studied in double-blind, crossover fashion. Single mg i.v. dose of 500 mg LEV or 25 mg BRV will be used, with infusion time over 15 minutes; primary outcome measure will be same.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Photosensitive Epilepsy</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Compare rapidity of CNS effects of levetiracetam (LEV) &amp; brivaracetam (BRV) within same pt-(randomized, two-way crossover, dbl-blind in total 16 pts w/epilepsy. Pt 1: IV infusion over 15 min BRV will also be administered as 15-min.infusion. BRV vs LEV in randomized double blinded, crossover fashion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pt 2 Op I:Assuming statistically signify. diff. in rapidity of CNS action has been observed from an analysis of data set in Pt 1,will proceed w/ Pt 2Opt I. Levetiracetam (LEV) or brivaracetam (BRV administered in randomized, two-way crossover, dbl-blind design as IV infusion over 5 min. to another cohort of 8 pts w/photosensitive epilepsy OR Pt 2,Opt II: Assuming no statistically signif. diff. in rapidity of CNS action has been observed from an analysis of data set in Pt 1, will proceed w/Pt 2,Opt II. LEV or BRV will be administered, in randomized, two-way crossover, dbl-blind design as IV infusion over again 15 min. to another cohort of 8 pts w/ photosensitive epilepsy. LEV will be given as 500 mg dose &amp; BRV as 25 mg dose. BRV vs LEV in randomized double blinded, crossover fashion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BRV vs LEV in randomized double blinded, crossover fashion</intervention_name>
    <description>Single dose intravenous administration of BRV 100 mg over a 15 minutes period. On a subsequent occasion, (approximately 2 weeks later), the patient is crossed over to the other drug at a singular dose. On both occasions, intermittent photic stimulation is done 10 times in a two hour period. IPS is again conducted in the cross over portion as well. Coincident with IPS stimulation 10 blood samples will be drawn for BRV or LEV plasma concentration.</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <other_name>Intermit pho stim respect over 2 hours/each of 2 study days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 18 and 65 years of age

          -  Male or female

          -  PPR at minimum at 60,50,40,30,25,20,18 or 16 Hz as upper threshold

          -  Drug na√Øve or at most with up to 4 AEDs, not being LEV or BRV

        Exclusion Criteria:

          -  Current treatment with more than 4 AEDs

          -  LEV or BRV as current treatment or used in the previous month.

          -  History of severe side-effects or psychological side-effects with LEV or BRV use

          -  Being pregnant or insufficiently protected against pregnancy (see also ref 31) or
             lactating Female

          -  Serious internal medical disease (renal/hepatic/cardiovascular disease) as deemed by
             the on-site physician (WER)

          -  History of psychiatric disease that has been a reason for acute hospitalisation for
             their condition of depression, schizophrenia, mania, delirium or aggressive behaviour

          -  History of status epilepticus

          -  History of significant ethanol or illicit drug use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William E Rosenfeld, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comprehensive Epilepsy Care Center for Children &amp; Adults</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Comprehensive Epilepsy Care Center For Children And Adults</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>June 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsy, Reflex</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

